Alexander Chehrazi-Raffle, M.D.

Medical oncologist Alexander Chehrazi-Raffle, M.D., has always had an interest in medicine. As a highschooler he was inspired to become a physician when he shadowed doctors and saw firsthand the tremendous impact that physicians have on people’s lives. Dr. Chehrazi-Raffle specializes in caring for patients with genitourinary cancers and aims to provide a patient-centered experience where people play an active role in developing a treatment plan uniquely tailored to their needs. His goal in providing care is to educate, counsel and advocate for patients with the hope of improving patient outcomes and establishing a trusted bond that will endure for years to come. 

Dr. Chehrazi-Raffle has published more than a dozen peer-reviewed case studies and research papers. As a City of Hope fellow, he became co-investigator on four ongoing clinical trials when he joined the faculty. His work on a precision medicine study to help predict treatment success in patients with advanced kidney cancer was published in the Journal of Immunotherapy of Cancer and garnered a merit award at the International Kidney Cancer Symposium.

Awards

• 2021, Conquer Cancer Merit Award, American Society of Clinical Oncology
• 2020, Merit Award for Oral Presentation, International Kidney Cancer Symposium
• 2014, MD with Distinction in Research Award, Rosalind Franklin University of Medicine and Science
• 2013, Global Health Project Scholarship, Rosalind Franklin University of Medicine and Science

Memberships

• 2020-present, Harbor-UCLA Hematology/Oncology Interest Group, Founding Member
• 2020-present, Kidney Cancer Association
• 2019-present, American Society of Hematology
• 2019-present, American Society of Clinical Oncology
• 2019-present, Society for Immunotherapy of Cancer
• 2017-present,  American College of Physicians
• 2017-2019, Graduation Medical Education Committee, Resident Representative

• Chehrazi-Raffle A, Tukachinsky H, Toye E, Sivakumar S, Schrock AB, Bergom HE, Ebrahimi H, Pal S, Dorff T, Agarwal N, Mahal BA, Oxnard GR, Hwang J, Antonarakis ES. Unique spectrum of activating BRAF alterations in prostate cancer. Clin Cancer Res. 2023 Jul 21:CCR-23-1393. PMID: 37477913. 
• Chehrazi-Raffle A, Leong S, Ali S, Kim T, Melamed S, Li X, Zengin Z, Meza L, Chawla N, Govindarajan A, Castro D, Mercier B, Ebrahimi H, Dizman N, Tripathi N, Sayegh N, Rock A, Yeh J, Pal SK, Onyshchenko M. Real-World Outcomes of Latinx Versus Non-Latinx Patients Treated With First-Line Immunotherapy for Metastatic Renal-Cell Carcinoma. Oncologist. 2023 Jul 11: PMID: 37432304. 
• Barata PC, Chehrazi-Raffle A, Allman KD, Asnis-Alibozek A, Kasturi V, Pal SK. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial. Oncologist. 2023 Jun 14:oyad132. PMID: 37315114. 
• Ebrahimi H, Castro DV, Feng MI, Prajapati SR, Lee KO, Chan EH, Paul T, Sehgal I, Patel J, Li X, Zengin ZB, Meza L, Mercier BD, Hsu J, Govindarajan A, Chawla N, Dizman N, Bergerot CD, Rock A, Liu S, Tripathi A, Dorff T, Pal SK, Chehrazi-Raffle A. Examining Exclusion Criteria in Advanced Prostate Cancer Clinical Trials: An Assessment of recommendations From the American Society Of Clinical Oncology and Friends of Cancer Research. Clin Genitourin Cancer. 2023 May 24:S1558-7673(23) PMID: 37301665. 
• Chehrazi-Raffle A, Muddasani R, Dizman N, Hsu J, Meza L, Zengin ZB, Malhotra J, Chawla N, Dorff T, Contente-Cuomo T, Dinwiddie D, McDonald BR, McDaniel T, Trent JM, Baehner FL, Murtaza M, Pal SK. Ultrasensitive Circulating Tumor DNA Pilot Study Distinguishes Complete Response and Partial Response With Immunotherapy in Patients With Metastatic Renal Cell Carcinoma. JCO Precis Oncol. 2023 Apr;7:. PMID: 37027813; PMCID: PMC10309555. 
• Chawla NS, Sayegh N, Prajapati S, Chan E, Pal SK, Chehrazi-Raffle A. An Update on the Treatment of Papillary Renal Cell Carcinoma. Cancers (Basel). 2023 Jan 17;15(3):565. PMCID: PMC9913225. 
• Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nat Med. 2022 Apr;28(4):704-712. PMID: 35228755; PMCID: PMC9018425. 
• Chehrazi-Raffle A, Dorff TB. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy. JCO Oncol Pract. 2022 Feb;18(2):97-98. PMID: 34559572. 
• Zengin ZB, Chehrazi-Raffle A, Salgia NJ, Muddasani R, Ali S, Meza L, Pal SK. Targeted therapies: Expanding the role of FGFR3 inhibition in urothelial carcinoma. Urol Oncol. 2022 Feb;40(2):25-36. PMID: 34840077. 
• Salgia NJ, Chehrazi-Raffle A, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK.  Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Medicine 10,no. 16 (2002):5671-80.